Compare DTCX & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DTCX | BNR |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.7M | 126.5M |
| IPO Year | 2021 | 2019 |
| Metric | DTCX | BNR |
|---|---|---|
| Price | $2.07 | $16.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 286.0K | 49.9K |
| Earning Date | 04-13-2026 | 06-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,446.00 | N/A |
| Revenue This Year | N/A | $111.65 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.51 | $6.79 |
| 52 Week High | $3.80 | $41.72 |
| Indicator | DTCX | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 47.98 | 73.89 |
| Support Level | $1.84 | $15.61 |
| Resistance Level | $2.27 | $18.59 |
| Average True Range (ATR) | 0.15 | 1.38 |
| MACD | -0.01 | 0.46 |
| Stochastic Oscillator | 51.21 | 100.00 |
Datacentrex Inc is a digital infrastructure and capital deployment company that owns and operates Scrypt compute assets and evaluates strategic transactions across asset-backed operating businesses. Its current operating platform is centered on owned and operated Scrypt-based proof-of-work compute deployed through third-party colocation facilities. Datacentrex monetizes this compute through hashrate marketplace mechanisms and manages a treasury of digital assets and cash in a manner intended to preserve capital and support opportunistic, accretive deployment. The company's operations are principally operated remotely at various data centers throughout the United States.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.